Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ACELYRIN, Inc.SLRN · Entity 79310 | Director · Chief Executive Officer | April 01, 2024 | April 03, 2024 |
| Cue Biopharma, Inc.CUE · Entity 6301 | Director · Chief Executive Officer | October 12, 2026 | October 15, 2026 |
| Horizon Therapeutics Public Ltd CoHZNP · Entity 109157 | EVP, Head of R&D and CSO | January 21, 2020 | January 23, 2020 |
| Surrozen, Inc./DESRZN · Entity 6092 | Director | May 14, 2025 | May 15, 2025 |
| Third Harmonic Bio, Inc.THRD · Entity 76517 | Director | October 26, 2022 | October 27, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ACELYRIN, Inc.
Report date April 01, 2024 · Filed April 03, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,577,374 |
Reported balance
After 2024-04-01 transaction · row 1
1 source rowRow 1 · 2024-04-01 · Sale · Disposed 9,961 · Balance 1,577,374 F1: The sale reported on this Form 4 was effected pursuant to the Issuer's policy requiring sell-to-cover to satisfy certain tax obligations of the Reporting Person incurred with the vesting and settlement of certain Restricted Stock Units, and does not represent a discretionary sale by the Reporting Person. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices no more than $6.655 and no less than $6.600, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 487,205 |
Reported balance
Holding disclosure · report date 2024-04-01 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 487,205 F3: Shares held directly by Shao-Lee Lin 2020 Gift Trust Dtd 7/16/20, for which the Reporting Person's spouse serves as trustee. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 677,813 |
Reported balance
Holding disclosure · report date 2024-04-01 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 677,813 F4: Shares held directly by Shao-Lee Lin, Trustee of the Shao-Lee Lin Trust u/a/d September 23, 2005, for which the Reporting Person serves as trustee. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 354,969 |
Reported balance
Holding disclosure · report date 2024-04-01 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 354,969 F5: Shares held directly by Lin Family 2020 Gift Trust Dtd 7/16/20, for which the Reporting Person's spouse shares voting and investment power. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 349,898 |
Reported balance
Holding disclosure · report date 2024-04-01 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 349,898 F6: Shares held directly by Susie Jun 2020 Gift Trust dtd 7/16/20, for which the Reporting Person serves as trustee. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 5,070 |
Reported balance
Holding disclosure · report date 2024-04-01 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 5,070 F7: Shares held directly by Susie Jun, Trustee of the Susie Jun Trust U/A/D September 23, 2005, for which the Reporting Person's spouse serves as trustee. |
Filing footnotes · ownership attribution and instrument terms
F1: The sale reported on this Form 4 was effected pursuant to the Issuer's policy requiring sell-to-cover to satisfy certain tax obligations of the Reporting Person incurred with the vesting and settlement of certain Restricted Stock Units, and does not represent a discretionary sale by the Reporting Person.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices no more than $6.655 and no less than $6.600, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3: Shares held directly by Shao-Lee Lin 2020 Gift Trust Dtd 7/16/20, for which the Reporting Person's spouse serves as trustee.
F4: Shares held directly by Shao-Lee Lin, Trustee of the Shao-Lee Lin Trust u/a/d September 23, 2005, for which the Reporting Person serves as trustee.
F5: Shares held directly by Lin Family 2020 Gift Trust Dtd 7/16/20, for which the Reporting Person's spouse shares voting and investment power.
F6: Shares held directly by Susie Jun 2020 Gift Trust dtd 7/16/20, for which the Reporting Person serves as trustee.
F7: Shares held directly by Susie Jun, Trustee of the Susie Jun Trust U/A/D September 23, 2005, for which the Reporting Person's spouse serves as trustee.
Cue Biopharma, Inc.
Report date October 12, 2026 · Filed October 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 694,908 |
Ending reported balance
After 2026-10-12 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-10-12 · Sale · Disposed 10,000 · Balance 695,995 F1: The sales reported represent shares sold pursuant to the Issuer's Company-Wide Policy and do not represent discretionary transactions by the Reporting Person. These sales were made automatically to satisfy mandatory tax withholding obligations through a "sell-to-cover" transaction in connection with the vesting and settlement of restricted stock units, and the Reporting Person did not exercise any control over the timing, price or number of shares sold. Row 2 · 2026-10-12 · Sale · Disposed 1,087 · Balance 694,908 F1: The sales reported represent shares sold pursuant to the Issuer's Company-Wide Policy and do not represent discretionary transactions by the Reporting Person. These sales were made automatically to satisfy mandatory tax withholding obligations through a "sell-to-cover" transaction in connection with the vesting and settlement of restricted stock units, and the Reporting Person did not exercise any control over the timing, price or number of shares sold. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported represent shares sold pursuant to the Issuer's Company-Wide Policy and do not represent discretionary transactions by the Reporting Person. These sales were made automatically to satisfy mandatory tax withholding obligations through a "sell-to-cover" transaction in connection with the vesting and settlement of restricted stock units, and the Reporting Person did not exercise any control over the timing, price or number of shares sold.
Horizon Therapeutics Public Ltd Co
Report date January 21, 2020 · Filed January 23, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 109,668 |
Ending reported balance
After 2020-01-21 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2020-01-21 · Grant · Acquired 6,129 · Balance 112,384 F1: On January 4, 2019, the reporting person was granted performance-based restricted stock units (PSUs) of the Issuer, which vest upon the satisfaction of certain performance criteria. On January 21, 2020, such performance criteria were met, and the PSUs vested as to the number of shares reported in Table I above. The remaining ordinary shares subject to the PSUs vest in equal annual installments on January 21, 2021 and January 21, 2022. Row 2 · 2020-01-21 · Tax withholding · Disposed 2,716 · Balance 109,668 |
| Performance Restricted Stock Units (PSUs)SEC Table II · derivative / convertible security | Direct | 12,262 |
Reported balance
After 2020-01-21 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-01-21 · Grant · Acquired 12,262 · Balance 12,262 F2: Each PSU represents a contingent right to receive one ordinary share of the Issuer. F1: On January 4, 2019, the reporting person was granted performance-based restricted stock units (PSUs) of the Issuer, which vest upon the satisfaction of certain performance criteria. On January 21, 2020, such performance criteria were met, and the PSUs vested as to the number of shares reported in Table I above. The remaining ordinary shares subject to the PSUs vest in equal annual installments on January 21, 2021 and January 21, 2022. |
Filing footnotes · ownership attribution and instrument terms
F1: On January 4, 2019, the reporting person was granted performance-based restricted stock units (PSUs) of the Issuer, which vest upon the satisfaction of certain performance criteria. On January 21, 2020, such performance criteria were met, and the PSUs vested as to the number of shares reported in Table I above. The remaining ordinary shares subject to the PSUs vest in equal annual installments on January 21, 2021 and January 21, 2022.
F2: Each PSU represents a contingent right to receive one ordinary share of the Issuer.
Surrozen, Inc./DE
Report date May 14, 2025 · Filed May 15, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.50 · Expires 2035-05-14 | Direct | 1,333 |
Reported balance
After 2025-05-14 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-05-14 · Grant · Acquired 1,333 · Balance 1,333 F1: The options vest and become exercisable on the anniversary of the grant date, subject to continuous service as a director. |
Filing footnotes · ownership attribution and instrument terms
F1: The options vest and become exercisable on the anniversary of the grant date, subject to continuous service as a director.
Third Harmonic Bio, Inc.
Report date October 26, 2022 · Filed October 27, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.83 · Expires 2032-10-25 | Direct | 13,667 |
Reported balance
After 2022-10-26 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-10-26 · Grant · Acquired 13,667 · Balance 13,667 F1: The option vests over a 8-month period: 1/8th on October 26, 2022, after which 1/8th of the total shares vest monthly, subject to continued service through each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests over a 8-month period: 1/8th on October 26, 2022, after which 1/8th of the total shares vest monthly, subject to continued service through each vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Principia Biopharma Inc.
Report date September 28, 2020 · Filed September 28, 2020
Section 16 reporting ended · disclosed 2020-09-28. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $27.81 · Expires 2029-04-15 | Direct | 0 |
Reported balance
After 2020-09-28 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-09-28 · Disposition to issuer · Disposed 20,475 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of August 16, 2020, by and among Principia Biopharma Inc. (the "Issuer"), Sanofi ("Sanofi") and Kortex Acquisition Corp. ("Purchaser") (the "Merger Agreement"), on September 28, 2020, Purchaser merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Sanofi (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options. |
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $31.77 · Expires 2029-06-10 | Direct | 0 |
Reported balance
After 2020-09-28 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-09-28 · Disposition to issuer · Disposed 10,240 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of August 16, 2020, by and among Principia Biopharma Inc. (the "Issuer"), Sanofi ("Sanofi") and Kortex Acquisition Corp. ("Purchaser") (the "Merger Agreement"), on September 28, 2020, Purchaser merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Sanofi (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options. |
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $62.66 · Expires 2030-06-03 | Direct | 0 |
Reported balance
After 2020-09-28 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-09-28 · Disposition to issuer · Disposed 10,240 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of August 16, 2020, by and among Principia Biopharma Inc. (the "Issuer"), Sanofi ("Sanofi") and Kortex Acquisition Corp. ("Purchaser") (the "Merger Agreement"), on September 28, 2020, Purchaser merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Sanofi (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger, dated as of August 16, 2020, by and among Principia Biopharma Inc. (the "Issuer"), Sanofi ("Sanofi") and Kortex Acquisition Corp. ("Purchaser") (the "Merger Agreement"), on September 28, 2020, Purchaser merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Sanofi (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 28, 2020 Filed Sep 28, 2020 17:25 UTC | Principia Biopharma Inc. PRNB · Entity 146423 | Disposition to issuerDirector Stock Option (right to buy) · Derivative | 10,240 | Not disclosed Strike: $31.77 | Not disclosed |
DisclosureSEC source: 0001209191-20-052231 · doc4.xml · derivative · entry 2 Lin Shao-Lee · CIK 0001725092 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,240 shares Expires 2029-06-10 F1 · kind: Pursuant to the Agreement and Plan of Merger, dated as of August 16, 2020, by and among Principia Biopharma Inc. (the "Issuer"), Sanofi ("Sanofi") and Kortex Acquisition Corp. ("Purchaser") (the "Merger Agreement"), on September 28, 2020, Purchaser merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Sanofi (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options. F1 · price: Pursuant to the Agreement and Plan of Merger, dated as of August 16, 2020, by and among Principia Biopharma Inc. (the "Issuer"), Sanofi ("Sanofi") and Kortex Acquisition Corp. ("Purchaser") (the "Merger Agreement"), on September 28, 2020, Purchaser merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Sanofi (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options. F1 · derivative.exercise_date: Pursuant to the Agreement and Plan of Merger, dated as of August 16, 2020, by and among Principia Biopharma Inc. (the "Issuer"), Sanofi ("Sanofi") and Kortex Acquisition Corp. ("Purchaser") (the "Merger Agreement"), on September 28, 2020, Purchaser merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Sanofi (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options. Read SEC document |
| September 28, 2020 Filed Sep 28, 2020 17:25 UTC | Principia Biopharma Inc. PRNB · Entity 146423 | Disposition to issuerDirector Stock Option (right to buy) · Derivative | 20,475 | Not disclosed Strike: $27.81 | Not disclosed |
DisclosureSEC source: 0001209191-20-052231 · doc4.xml · derivative · entry 1 Lin Shao-Lee · CIK 0001725092 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,475 shares Expires 2029-04-15 F1 · kind: Pursuant to the Agreement and Plan of Merger, dated as of August 16, 2020, by and among Principia Biopharma Inc. (the "Issuer"), Sanofi ("Sanofi") and Kortex Acquisition Corp. ("Purchaser") (the "Merger Agreement"), on September 28, 2020, Purchaser merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Sanofi (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options. F1 · price: Pursuant to the Agreement and Plan of Merger, dated as of August 16, 2020, by and among Principia Biopharma Inc. (the "Issuer"), Sanofi ("Sanofi") and Kortex Acquisition Corp. ("Purchaser") (the "Merger Agreement"), on September 28, 2020, Purchaser merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Sanofi (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options. F1 · derivative.exercise_date: Pursuant to the Agreement and Plan of Merger, dated as of August 16, 2020, by and among Principia Biopharma Inc. (the "Issuer"), Sanofi ("Sanofi") and Kortex Acquisition Corp. ("Purchaser") (the "Merger Agreement"), on September 28, 2020, Purchaser merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Sanofi (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options. Read SEC document |
| June 04, 2020 Filed Jun 8, 2020 20:05 UTC | Principia Biopharma Inc. PRNB · Entity 146423 | GrantDirector Stock Option (right to buy) · Derivative | 10,240 | $0.00 Strike: $62.66 | $0.00 |
DisclosureSEC source: 0001209191-20-035141 · doc4.xml · derivative · entry 1 Lin Shao-Lee · CIK 0001725092 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,240 Underlying: Common Stock · 10,240 shares Expires 2030-06-03 F1 · derivative.exercise_date: The stock option vests in equal monthly installments over a one year period such that the option is fully vested on the first anniversary of the date of grant, subject to the continuing service of the Reporting Person on each vesting date. Read SEC document |
| January 21, 2020 Filed Jan 23, 2020 16:22 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | GrantPerformance Restricted Stock Units (PSUs) · Derivative | 12,262 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-004668 · doc4.xml · derivative · entry 3 Lin Shao-Lee · CIK 0001725092 · EVP, Head of R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,262 Underlying: Ordinary Shares · 12,262 shares Expires not disclosed F2 · derivative.exercise_price: Each PSU represents a contingent right to receive one ordinary share of the Issuer. F1 · kind: On January 4, 2019, the reporting person was granted performance-based restricted stock units (PSUs) of the Issuer, which vest upon the satisfaction of certain performance criteria. On January 21, 2020, such performance criteria were met, and the PSUs vested as to the number of shares reported in Table I above. The remaining ordinary shares subject to the PSUs vest in equal annual installments on January 21, 2021 and January 21, 2022. F1 · derivative.exercise_date: On January 4, 2019, the reporting person was granted performance-based restricted stock units (PSUs) of the Issuer, which vest upon the satisfaction of certain performance criteria. On January 21, 2020, such performance criteria were met, and the PSUs vested as to the number of shares reported in Table I above. The remaining ordinary shares subject to the PSUs vest in equal annual installments on January 21, 2021 and January 21, 2022. F1 · derivative.expiration_date: On January 4, 2019, the reporting person was granted performance-based restricted stock units (PSUs) of the Issuer, which vest upon the satisfaction of certain performance criteria. On January 21, 2020, such performance criteria were met, and the PSUs vested as to the number of shares reported in Table I above. The remaining ordinary shares subject to the PSUs vest in equal annual installments on January 21, 2021 and January 21, 2022. Read SEC document |
| January 21, 2020 Filed Jan 23, 2020 16:22 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Tax withholdingOrdinary Shares | 2,716 | $38.25 | $103,887.00 |
DisclosureSEC source: 0001209191-20-004668 · doc4.xml · nonDerivative · entry 2 Lin Shao-Lee · CIK 0001725092 · EVP, Head of R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,668 Read SEC document |
| January 21, 2020 Filed Jan 23, 2020 16:22 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | GrantOrdinary Shares | 6,129 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-004668 · doc4.xml · nonDerivative · entry 1 Lin Shao-Lee · CIK 0001725092 · EVP, Head of R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,384 F1 · kind: On January 4, 2019, the reporting person was granted performance-based restricted stock units (PSUs) of the Issuer, which vest upon the satisfaction of certain performance criteria. On January 21, 2020, such performance criteria were met, and the PSUs vested as to the number of shares reported in Table I above. The remaining ordinary shares subject to the PSUs vest in equal annual installments on January 21, 2021 and January 21, 2022. Read SEC document |
| January 05, 2020 Filed Jan 7, 2020 18:21 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Exercise / conversionRestricted Stock Units (RSU) · Derivative | 32,362 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-002344 · doc4.xml · derivative · entry 9 Lin Shao-Lee · CIK 0001725092 · EVP, Head of R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,363 Underlying: Ordinary Shares · 32,362 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each RSU represents a contingent right to receive one ordinary share of the Issuer. F7 · derivative.exercise_date: The RSU's vest 1/3rd annually on each anniversary of January 5, 2018. F7 · derivative.expiration_date: The RSU's vest 1/3rd annually on each anniversary of January 5, 2018. Read SEC document |
| January 05, 2020 Filed Jan 7, 2020 18:21 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Exercise / conversionRestricted Stock Units (RSU) · Derivative | 17,982 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-002344 · doc4.xml · derivative · entry 8 Lin Shao-Lee · CIK 0001725092 · EVP, Head of R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,966 Underlying: Ordinary Shares · 17,982 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each RSU represents a contingent right to receive one ordinary share of the Issuer. F6 · derivative.exercise_date: The RSU's vest 1/3rd annually on each anniversary of January 5, 2019. F6 · derivative.expiration_date: The RSU's vest 1/3rd annually on each anniversary of January 5, 2019. Read SEC document |
| January 05, 2020 Filed Jan 7, 2020 18:21 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Tax withholdingOrdinary Shares | 38,100 | $36.10 | $1,375,410.00 |
DisclosureSEC source: 0001209191-20-002344 · doc4.xml · nonDerivative · entry 5 Lin Shao-Lee · CIK 0001725092 · EVP, Head of R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,255 Read SEC document |
| January 05, 2020 Filed Jan 7, 2020 18:21 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | GrantOrdinary Shares | 35,652 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-002344 · doc4.xml · nonDerivative · entry 4 Lin Shao-Lee · CIK 0001725092 · EVP, Head of R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,355 F3 · kind: On January 5, 2018, the reporting person was granted performance-based restricted stock units (PSUs) of the Issuer, which vest upon the satisfaction of certain performance criteria. On January 5, 2020, the PSUs vested as to the number of shares reported above. Read SEC document |
| January 05, 2020 Filed Jan 7, 2020 18:21 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Exercise / conversionOrdinary Shares | 50,344 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-002344 · doc4.xml · nonDerivative · entry 3 Lin Shao-Lee · CIK 0001725092 · EVP, Head of R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,703 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each RSU represents a contingent right to receive one ordinary share of the Issuer. Read SEC document |
| January 04, 2020 Filed Jan 7, 2020 18:21 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Exercise / conversionRestricted Stock Units (RSU) · Derivative | 17,892 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-002344 · doc4.xml · derivative · entry 7 Lin Shao-Lee · CIK 0001725092 · EVP, Head of R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,784 Underlying: Ordinary Shares · 17,892 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each RSU represents a contingent right to receive one ordinary share of the Issuer. F5 · derivative.exercise_date: The RSU's vest 1/4th annually on each anniversary of January 4, 2018. F5 · derivative.expiration_date: The RSU's vest 1/4th annually on each anniversary of January 4, 2018. Read SEC document |
| January 04, 2020 Filed Jan 7, 2020 18:21 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Tax withholdingOrdinary Shares | 8,113 | $36.10 | $292,879.30 |
DisclosureSEC source: 0001209191-20-002344 · doc4.xml · nonDerivative · entry 2 Lin Shao-Lee · CIK 0001725092 · EVP, Head of R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,359 Read SEC document |
| January 04, 2020 Filed Jan 7, 2020 18:21 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Exercise / conversionOrdinary Shares | 17,892 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-002344 · doc4.xml · nonDerivative · entry 1 Lin Shao-Lee · CIK 0001725092 · EVP, Head of R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,472 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each RSU represents a contingent right to receive one ordinary share of the Issuer. F2 · balance_after: Includes 1,049 ordinary shares of the Issuer acquired by the reporting person on November 29, 2019 pursuant to an employee stock purchase program. Read SEC document |
| January 03, 2020 Filed Jan 7, 2020 18:21 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | GrantRestricted Stock Units (RSU) · Derivative | 36,284 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-002344 · doc4.xml · derivative · entry 6 Lin Shao-Lee · CIK 0001725092 · EVP, Head of R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,284 Underlying: Ordinary Shares · 36,284 shares Expires not disclosed F1 · derivative.exercise_price: Each RSU represents a contingent right to receive one ordinary share of the Issuer. F4 · derivative.exercise_date: The RSU's vest 1/3rd annually on each anniversary of January 5, 2020. F4 · derivative.expiration_date: The RSU's vest 1/3rd annually on each anniversary of January 5, 2020. Read SEC document |
| June 11, 2019 Filed Jun 11, 2019 18:57 UTC | Principia Biopharma Inc. PRNB · Entity 146423 | GrantDirector Stock Option (right to buy) · Derivative | 10,240 | $0.00 Strike: $31.77 | $0.00 |
DisclosureSEC source: 0001209191-19-036237 · doc4.xml · derivative · entry 1 Lin Shao-Lee · CIK 0001725092 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,240 Underlying: Common Stock · 10,240 shares Expires 2029-06-10 F1 · derivative.exercise_date: The stock option vests in equal monthly installments over a one year period such that the option is fully vested on the first anniversary of the date of grant, subject to the continuing service of the Reporting Person on each vesting date. Read SEC document |
| April 16, 2019 Filed Apr 18, 2019 16:23 UTC | Principia Biopharma Inc. PRNB · Entity 146423 | GrantDirector Stock Option (right to buy) · Derivative | 20,475 | $0.00 Strike: $27.81 | $0.00 |
DisclosureSEC source: 0001209191-19-025238 · doc4.xml · derivative · entry 1 Lin Shao-Lee · CIK 0001725092 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,475 Underlying: Common Stock · 20,475 shares Expires 2029-04-15 F1 · derivative.exercise_date: The stock option vests in equal monthly installments over a three year period such that the option is fully vested on the third anniversary of the date of grant, subject to the continuing service of the Reporting Person on each vesting date. Read SEC document |
| February 20, 2019 Filed Feb 22, 2019 17:23 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Tax withholdingOrdinary Shares | 15,795 | $21.54 | $340,224.30 |
DisclosureSEC source: 0001209191-19-012697 · doc4.xml · nonDerivative · entry 2 Lin Shao-Lee · CIK 0001725092 · EVP, Head of R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,531 Read SEC document |
| February 20, 2019 Filed Feb 22, 2019 17:23 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | GrantOrdinary Shares | 35,652 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-012697 · doc4.xml · nonDerivative · entry 1 Lin Shao-Lee · CIK 0001725092 · EVP, Head of R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,326 F1 · kind: On January 5, 2018, the reporting person was granted performance-based restricted stock units (PSUs) of the Issuer, which vest upon the satisfaction of certain performance criteria. On February 20, 2019, the PSUs vested as to the number of shares reported above, upon the Issuer's determination that certain performance criteria had been met. F1 · shares: On January 5, 2018, the reporting person was granted performance-based restricted stock units (PSUs) of the Issuer, which vest upon the satisfaction of certain performance criteria. On February 20, 2019, the PSUs vested as to the number of shares reported above, upon the Issuer's determination that certain performance criteria had been met. Read SEC document |
| January 05, 2019 Filed Jan 8, 2019 20:40 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Exercise / conversionRestricted Stock Units (RSU) · Derivative | 32,362 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-002935 · doc4.xml · derivative · entry 7 Lin Shao-Lee · CIK 0001725092 · EVP, Head of R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,725 Underlying: Ordinary Shares · 32,362 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each RSU represents a contingent right to receive one ordinary share of the Issuer. F4 · derivative.exercise_date: The RSU's vest 1/3rd annually on each anniversary of January 5, 2018. F4 · derivative.expiration_date: The RSU's vest 1/3rd annually on each anniversary of January 5, 2018. Read SEC document |
| January 05, 2019 Filed Jan 8, 2019 20:40 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Tax withholdingOrdinary Shares | 14,337 | $20.39 | $292,331.43 |
DisclosureSEC source: 0001209191-19-002935 · doc4.xml · nonDerivative · entry 4 Lin Shao-Lee · CIK 0001725092 · EVP, Head of R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,674 Read SEC document |
| January 05, 2019 Filed Jan 8, 2019 20:40 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Exercise / conversionOrdinary Shares | 32,362 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-002935 · doc4.xml · nonDerivative · entry 3 Lin Shao-Lee · CIK 0001725092 · EVP, Head of R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,011 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each RSU represents a contingent right to receive one ordinary share of the Issuer. Read SEC document |
| January 04, 2019 Filed Jan 8, 2019 20:40 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | GrantRestricted Stock Units (RSU) · Derivative | 53,948 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-002935 · doc4.xml · derivative · entry 6 Lin Shao-Lee · CIK 0001725092 · EVP, Head of R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,948 Underlying: Ordinary Shares · 53,948 shares Expires not disclosed F1 · derivative.exercise_price: Each RSU represents a contingent right to receive one ordinary share of the Issuer. F3 · derivative.exercise_date: The RSU's vest 1/3rd annually on each anniversary of January 5, 2019. F3 · derivative.expiration_date: The RSU's vest 1/3rd annually on each anniversary of January 5, 2019. Read SEC document |
| January 04, 2019 Filed Jan 8, 2019 20:40 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Exercise / conversionRestricted Stock Units (RSU) · Derivative | 17,891 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-002935 · doc4.xml · derivative · entry 5 Lin Shao-Lee · CIK 0001725092 · EVP, Head of R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,676 Underlying: Ordinary Shares · 17,891 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each RSU represents a contingent right to receive one ordinary share of the Issuer. F2 · derivative.exercise_date: The RSU's vest 1/4th annually on each anniversary of January 4, 2018. F2 · derivative.expiration_date: The RSU's vest 1/4th annually on each anniversary of January 4, 2018. Read SEC document |
| January 04, 2019 Filed Jan 8, 2019 20:40 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Tax withholdingOrdinary Shares | 8,242 | $20.39 | $168,054.38 |
DisclosureSEC source: 0001209191-19-002935 · doc4.xml · nonDerivative · entry 2 Lin Shao-Lee · CIK 0001725092 · EVP, Head of R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,649 Read SEC document |
| January 04, 2019 Filed Jan 8, 2019 20:40 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Exercise / conversionOrdinary Shares | 17,891 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-002935 · doc4.xml · nonDerivative · entry 1 Lin Shao-Lee · CIK 0001725092 · EVP, Head of R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,891 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each RSU represents a contingent right to receive one ordinary share of the Issuer. Read SEC document |
| May 03, 2018 Filed May 7, 2018 20:48 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | GrantRestricted Stock Units (RSU) · Derivative | 97,087 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-028490 · doc4.xml · derivative · entry 1 Lin Shao-Lee · CIK 0001725092 · EVP, Head of R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,087 Underlying: Ordinary Shares · 97,087 shares Expires not disclosed F1 · derivative.exercise_price: Each RSU represents a contingent right to receive one ordinary share of the Issuer. F2 · date: The RSU's were approved by the Issuer's Compensation Committee on January 5, 2018, subject to shareholder approval of certain amendments to the Issuer's 2014 Equity Incentive Plan (the "Plan") under which the RSU's were granted. The Issuer's shareholders approved the amendments to the Plan on May 3, 2018. F3 · derivative.exercise_date: The RSU's vest 1/3rd annually on each anniversary of January 5, 2018. F1 · derivative.expiration_date: Each RSU represents a contingent right to receive one ordinary share of the Issuer. Read SEC document |
| January 04, 2018 Filed Jan 5, 2018 17:04 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | GrantRestricted Stock Units · Derivative | 71,567 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-002497 · doc4.xml · derivative · entry 2 Lin Shao-Lee · CIK 0001725092 · EVP, Head of R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,567 Underlying: Ordinary shares · 71,567 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer. F3 · derivative.exercise_date: The shares subject to the restricted stock units shall vest in four equal annual installments, beginning on the first anniversary of the grant date. F2 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer. Read SEC document |
| January 04, 2018 Filed Jan 5, 2018 17:04 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | GrantStock Option (Right to Buy) · Derivative | 146,685 | $0.00 Strike: $15.37 | $0.00 |
DisclosureSEC source: 0001209191-18-002497 · doc4.xml · derivative · entry 1 Lin Shao-Lee · CIK 0001725092 · EVP, Head of R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,685 Underlying: Ordinary shares · 146,685 shares Expires 2028-01-03 F1 · derivative.exercise_date: 25% of the shares subject to the option vest and become exercisable on the first anniversary of the date of grant, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.